BioCentury on BioBusiness,
Product Discovery & Development
After 20 years, 2 companies and 1 rejection, FDA approves Marqibo for leukemia
Clawing towards approval
Monday, August 20, 2012
After 20 years in development at two companies, Marqibo
vincristine sulfate received accelerated approval from FDA this month
Therapeutics Inc. applied the lessons from a previous rejection by
conducting a more thoroughly adjudicated study in a new cancer setting. Talon
plans to launch the drug for late-stage acute lymphoblastic leukemia in 1Q13.
Marqibo is a nanoparticle-encapsulated
formulation of vincristine designed to allow for dose intensification of the
vinca alkaloid to facilitate activity against relapsed or refractory cancer
without exacerbating toxicities.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2014 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
If you are a current subscriber, log in below or in the upper right corner of this
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]